LHDX - Lucira Health jumps 111% on FDA authorization of combination COVID flu at-home test
- The US FDA has authorized an at-home test from Lucira Health ( NASDAQ: LHDX ) that can detect both COVID-19 and the flu.
- Shares are up 111% in after-hours trading.
- The authorization comes two days after the company filed for Chapter 11 bankruptcy, in part because of a delay in receiving the OK to market the test .
- The test provides results in about 30 minutes from nasal swab samples.
For further details see:
Lucira Health jumps 111% on FDA authorization of combination COVID, flu at-home test